Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy

被引:111
作者
Guadagnolo, BA
Li, SG
Neuberg, D
Ng, A
Hua, L
Silver, B
Stevenson, MA
Mauch, P
机构
[1] Harvard Radiat Oncol Residency Program, Joint Ctr Radiat Therapy, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA
[3] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA
[4] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 64卷 / 03期
关键词
follicular lymphoma; radiotherapy; second malignancy; cause of death;
D O I
10.1016/j.ijrobp.2005.08.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To analyze long-term outcomes and causes of death in patients receiving radiation therapy (RT) for localized, low-grade follicular lymphoma. Methods and Materials: Between 1972 and 2000, 106 patients with Stage I-II, Grade 1-2 follicular lymphoma received RT alone or radiation and chemotherapy (RT/CT). Seventy-four percent had Stage I, and 26% had Stage II disease. Seventy-six percent received RT alone, and 24% received combined RT/CT. Second malignancy rates were compared with an age- and sex-matched population. Results: Median follow-up was 12 years. Median survival time was 19 years. The 5-, 10-, and 15-year overall survival (OS) rates were 93%, 75%, and 62%, respectively. Age >= 60 was the only significant adverse prognostic factor with respect to OS. There were 35 deaths, 20 of which were attributable to lymphoma. Freedom from treatment failure (FFTF) rates at 5, 10, and 15 years were 72%, 46%, and 39%, respectively. Forty-seven patients (48%) relapsed. Tumor size >3 cm was the only significant adverse factor for FFTF. Observed incidence of second malignancy did not significantly exceed expected incidence. Conclusions: Although patients with early-stage, low-grade follicular lymphoma have long median survival, the leading cause of death remains lymphoma. However, patients receiving RT do not have significantly elevated cumulative incidence of second malignancy. (C) 2006 Elsevier Inc.
引用
收藏
页码:928 / 934
页数:7
相关论文
共 35 条
[1]   Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy [J].
Advani, R ;
Rosenberg, SA ;
Horning, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1454-1459
[2]   Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen:: a GELA cohort study on 2837 patients [J].
André, M ;
Mounier, N ;
Leleu, X ;
Sonet, A ;
Brice, P ;
Henry-Amar, M ;
Tilly, H ;
Coiffier, B ;
Bosly, A ;
Morel, P ;
Haioun, C ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
BLOOD, 2004, 103 (04) :1222-1228
[3]  
BESA PC, 1995, CANCER, V75, P2361, DOI 10.1002/1097-0142(19950501)75:9<2361::AID-CNCR2820750928>3.0.CO
[4]  
2-N
[5]  
BYRNE GE, 1977, CANCER TREAT REP, V61, P935
[6]  
CARABELL SC, 1979, CANCER, V43, P994, DOI 10.1002/1097-0142(197903)43:3<994::AID-CNCR2820430331>3.0.CO
[7]  
2-0
[8]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[9]  
CHAFFEY JT, 1977, CANCER TREAT REP, V61, P1149
[10]  
Chan WC, 1997, BLOOD, V89, P3909